Market Data
Market Cap₹6,226.21 Cr.
52W High₹1,599.55
Current Price₹1,351.95
52W Low₹661.65
Down from 52W High15.5 %
Face Value₹10
Performance
ROCE15.62 %
ROE13.54 %
EPS (TTM)₹6.61
EPS Prev Qtr₹7.96
EPS Last Year₹6.54
EBITDA Qtr₹43.82 Cr.
Book Value₹203
Financial Health
Debt/Equity0.37
Debt/Profit2.61
Total Assets₹1,603.81 Cr.
Promoter Holding45.82 %
Earning Power10.35 %
Valuation
Stock P/E47.6
Industry P/E33.81
Price to Book6.67
Price to Sales9.05
Graham Number₹359.89
Key Metrics
Face Value
₹10
About Senores Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Senores Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹6,226.21 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy ROCE of 18.26%, indicating efficient use of capital.
- ROE stands at 16.64%, reflecting strong returns generated on shareholders' equity.
- The Debt to Equity ratio of 0.39 suggests a conservative capital structure with moderate leverage.
- Promoter holding at 45.82% indicates significant management control and alignment of interests.
Weaknesses
- The P/E ratio of 48.25 is relatively high, suggesting the stock may be overvalued compared to peers.
- The P/B ratio of 8.03 is elevated, indicating potential overvaluation in terms of book value.
- The company does not currently offer a dividend yield, which may be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 161.76 | 170.95 | 175.19 | 180.21 |
| ↳ QoQ Growth | - | +5.7% | +2.5% | +2.9% |
| Expenses | 120.34 | 128.41 | 137 | 136.39 |
| Operating Profit | 41.42 | 42.54 | 38.19 | 43.82 |
| OPM % | 25.61% | 24.88% | 21.8% | 24.32% |
| Other Income | 5.41 | 7.39 | 17.67 | 2.81 |
| Interest | 6.19 | 5.33 | 8.46 | 7.17 |
| Depreciation | 8.09 | 7.86 | 9.3 | 9.94 |
| EBITDA | 49.51 | 50.4 | 47.49 | 53.76 |
| EBITDA Margin % | 30.61% | 29.48% | 27.11% | 29.83% |
| Profit Before Tax | 40.64 | 44.6 | 47.4 | 39.46 |
| Tax % | 25.89% | 24.71% | 22.64% | 22.83% |
| Net Profit | 30.12 | 33.58 | 36.67 | 30.45 |
| ↳ QoQ Growth | - | +11.5% | +9.2% | -17.0% |
| EPS | 6.54 | 7.29 | 7.96 | 6.61 |
Balance Sheet
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 30.51 | 46.05 | 46.05 |
| Reserves | 173.76 | 740.13 | 887.55 |
| Borrowings | 257.64 | 304.76 | 342.03 |
| Other Liabilities | 159.97 | 135.92 | 328.18 |
| Total Liabilities | 621.88 | 1226.86 | 1603.81 |
| Fixed Assets | 161.34 | 429.02 | 369.85 |
| CWIP | 17.77 | 44.17 | 17.46 |
| Investments | 0.01 | 0.01 | 4.29 |
| Other Assets | 442.76 | 753.66 | 1212.21 |
| Total Assets | 621.88 | 1226.86 | 1603.81 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -45.92 |
| Cash from Investing Activity | -429.48 |
| Cash from Financing Activity | 573.13 |
| Net Cash Flow | 97.73 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 45.8% | 45.8% | 45.82% | 45.82% |
| FIIs % | 4.28% | 3.35% | 3.64% | 6.62% |
| DIIs % | 8.62% | 9.32% | 9.61% | 9.77% |
| Public % | 31.09% | 31.94% | 31.64% | 29.25% |
| No. of Shareholders | 34,917 | 34,401 | 34,126 | 36,498 |
Major Shareholders (>1%)
- Swapnil Jatin ShahPromoter and Promoter Group7.72%
- Ashokbhai Vijaysinh BarotPromoter and Promoter Group7.48%
- Remus Pharmaceuticals LimitedPromoter and Promoter Group7.08%
- Renosen Pharmaceuticals Private LimitedPromoter and Promoter Group5.90%
As of 2026-06-30View all shareholders →